S napshot Treatment for non-small cell lung cancer and pancreatic cancer  Tarceva Treatment for prostate cancer XTAnDi Mainstay Products in Oncology Fiscal 2013 sales: ¥54.6 billion This product is used in the treatment of prostate cancer.  It was launched in the U.S. in 2012 for indications of  metastatic castration-resistant prostate cancer in  patients who have previously received docetaxel. It is  currently sold in over 25 countries and regions, including  Europe, North America and Japan. Fiscal 2013 sales: ¥44.7 billion Acofide was launched in Japan in June 2013 as the  first treatment for the indication of functional dyspepsia.  Astellas is co-promoting Acofide with Zeria Pharmaceutical Co., Ltd. DIFICLIR is an oral macrocyclic antibiotic with a selective  antibiotic spectrum. It was launched in Europe in 2012  as a treatment for  Clostridium difficile  infections in adults. Cimzia is the world’s first PEGylated anti-TNF (tumor  necrosis factor)-alpha antibody. It was launched in  Japan in March 2013 as a treatment for rheumatoid  arthritis. Astellas is co-promoting Cimzia with UCB  Japan Co., Ltd. Japan’s first SGLT2 inhibitor to receive approval for the  treatment of type 2 diabetes. It was launched in April  2014 and we co-promote it with Kotobuki Pharmaceu- tical Co., Ltd. and MSD K.K. Latest Innovative Products This product is a low-molecule drug developed to target  the epidermal growth factor receptor (EGFR) that plays  a key role in cancer formation and growth. In the U.S.,  Astellas is co-promoting Tarceva with Genentech, Inc. In  regions outside the U.S., Astellas has a license agree- ment with F. Hoffmann-La Roche Ltd. 2 cimzia for the treatment of adult patients with rheumatoid arthritis 1 Suglat for the treatment of type 2 diabetes 3 Acofide for the treatment of functional dyspepsia 4 DiFicliR for the treatment of  Clostridium difficile  infections 1 2 3 4 Annual Report 2014 _  Astellas Pharma Inc.  21